featured
Margetuximab Plus Pembrolizumab in Patients With Previously Treated, HER2-Positive Gastro-Esophageal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Margetuximab Plus Pembrolizumab in Patients With Previously Treated, HER2-Positive Gastro-Oesophageal Adenocarcinoma (CP-MGAH22-05): A Single-Arm, Phase 1b-2 Trial
Lancet Oncol 2020 Jul 09;[EPub Ahead of Print], DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, PC Enzinger, SH Park, PJ Gold, J Lacy, HS Hochster, SC Oh, YH Kim, KA Marrone, RJ Kelly, RA Juergens, JG Kim, JC Bendell, T Alcindor, SJ Sym, EK Song, CE Chee, Y Chao, S Kim, AC Lockhart, KL Knutson, J Yen, A Franovic, JL Nordstrom, D Li, J Wigginton, JK Davidson-Moncada, MK Rosales, YJ BangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.